<DOC>
	<DOCNO>NCT02100189</DOCNO>
	<brief_summary>This clinical trial study whether esophageal cytology plus fluorescence situ hybridization ( FISH ) equal good esophago-gastro-duodenoscopy ( EGD ) upper endoscopy early detection esophageal cancer . Genes unit deoxyribonucleic acid ( DNA ) chemical structure carry genetic information determine many human characteristic . Certain gene cancer cell may determine tumor grows spread may respond different drug . Part study test gene esophageal cell use FISH .</brief_summary>
	<brief_title>Esophageal Cytology With FISH Detecting Esophageal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine sponge cytology FISH reliable screen tool esophageal dysplasia/cancer , determine sensitivity specificity , compare gold standard procedure ( upper endoscopy ) . SECONDARY OBJECTIVES : I . Determine cytology screen FISH biomarkers cost effective upper endoscopy screen esophageal cancer surveillance esophageal metaplasia dysplasia . II . Determine limitations future need improve technique . OUTLINE : Participants swallow capsule ( Oesotest Actimed ) wait 10 minute sponge pull esophagus gentle traction string . Cytology sample sponge harvest analyzed FISH . Participants undergo standard EGD upper endoscopy .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Subjects know esophageal cancer diagnose previous endoscopy Adenocarcinoma Squamous cell carcinoma Patients determine risk esophageal cancer : Subjects history Barrett 's esophagus Subjects history low high grade dysplasia Subjects history gastroesophageal reflux disease ( GERD ) Subjects history esophagitis Subjects symptoms esophageal cancer ( EC ) refer endoscopy ( new onset dysphagia , weight loss , etc ) Patients must schedule procedure capable provide definitive pathological diagnosis evaluate complication esophageal sponge day study procedure , either : Upper endoscopy Surgical esophagectomy Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 3 ( Karnofsky &gt; = 30 % ) include Ability understand willingness sign write informed consent document Subjects severe , symptomatic dysphagia ( unable pas solid ) Subjects unable swallow tablet/pill reason Subjects previous esophagectomy Subjects esophageal varix Subjects unable provide consent Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>